Published in final edited form as:

Am J Kidney Dis. 2017 April ; 69(4): 498–505. doi:10.1053/j.ajkd.2016.07.034.

Preeclampsia and ESRD: The Role of Shared Risk Factors

Andrea G. Kattah, MD¹, Dawn C. Scantlebury, MBBS², Sanket Agarwal¹, Michelle M. Mielke, PhD³, Walter A. Rocca, MD, MPH³, Amy L. Weaver⁴, Lisa E. Vaughan⁴, Virginia M. Miller, PhD⁵, Tracey L. Weissgerber, PhD¹, Wendy White, MD⁶, and Vesna D. Garovic, MD¹

¹Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN

²Department of Cardiovascular Services, The Queen Elizabeth Hospital, Barbados

³Division of Epidemiology, Department of Health Sciences Research and Department of Neurology, Mayo Clinic, Rochester, MN, United States

⁴Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States

⁵Department of Physiology and Biomedical Engineering, Department of Surgery, Mayo Clinic, Rochester, MN, United States

⁶Division of Maternal Fetal Medicine; Mayo Clinic, Rochester, MN, United States

Abstract

Background—Several registry-based studies, using diagnostic codes, have suggested that preeclampsia is a risk factor for end-stage renal disease (ESRD). However, because the two diseases share risk factors, the true nature of their association remains uncertain. Our goals were to conduct a population-based study to determine the magnitude of the association between preeclampsia and ESRD and to evaluate the role of shared risk factors.

Corresponding author: Dr. Vesna D. Garovic, Mayo Clinic, Division of Nephrology and Hypertension, 200 First Street SW, Rochester, MN, 55905, Phone number: 507-266-1963, Fax: 507-266-7891, garovic.vesna@mayo.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Financial Disclosure: The authors declare that they have no other relevant financial interests.

Contributions: Research idea: AGK, VDG; study design: AGK, DCS, MMM, ALW, WW, VDG; data acquisition: SA, AGK, DCS; data analysis/interpretation: AGK, MMM, WAR, ALW, LEV, VMM, TLW, VDG. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. VDG takes responsibility that this study has been reported honestly, accurately and transparently; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Supplementary Material

Table S1: Diagnostic algorithms for hypertensive pregnancy disorders.

Table S2: Pregnancy outcomes.

Table S3: Diagnostic codes identified for cases and controls from all REP-affiliated providers.

Note: The supplementary material accompanying this article (doi:_____) is available at www.ajkd.org

Supplementary Material Descriptive Text for Online Delivery

Supplementary Table S1 (PDF). Diagnostic algorithms for hypertensive pregnancy disorders.

Supplementary Table S2 (PDF). Pregnancy outcomes. Supplementary Table S3 (PDF). Diagnostic codes identified for cases and controls from all REP-affiliated providers.

Study Design—Population-based, nested case-control study

Setting & Participants—The US Renal Data System was used to identify women with ESRD from a cohort of 34,581 women who gave birth in 1976–2010 in Olmsted County, Minnesota. Forty-four cases of ESRD were identified and each one was matched to 2 controls based on year of birth (± 1 year), age at first pregnancy (± 2 years), and parity (± 1 or ± 4).

Predictor—Preeclamptic pregnancy, confirmed by medical record review.

Outcome—End-stage renal disease.

Measurements—Pre-pregnancy serum creatinine and urine protein measurements were recorded. Comorbidities existing prior to pregnancy were abstracted from medical records, and included kidney disease, obesity, diabetes, and hypertension.

Results—There was evidence of kidney disease prior to the first pregnancy in 9 of 44 cases (21%) and 1 of 88 controls ($<1\%$). Per chart review, 8 of 44 (18%) cases vs 4 of 88 controls (5%) had preeclamptic pregnancies (unadjusted OR, 4.0; 95% CI, 1.21–13.28). The results were similar after independent adjustment for race, education, diabetes, or hypertension prior to pregnancy. However, the association was attenuated and no longer significant after adjustment for obesity (OR, 3.25; 95% CI, 0.93–11.37).

Limitations—The limited number of ESRD cases and missing data on pre-pregnancy kidney function.

Conclusions—Our findings confirm that there is a sizable association between preeclampsia and ESRD; however, obesity is a previously unexplored confounder. Pre-existing kidney disease was common, but not consistently coded or diagnosed.

Keywords

Preeclampsia; hypertension; pregnancy; hypertensive pregnancy disorders; toxemia; risk factor; end-stage renal disease (ESRD); obesity

Hypertension complicates approximately 8% of pregnancies and leads to significant maternal morbidity and mortality.(1) Certain long-term effects of hypertensive pregnancies on maternal health have been recognized, particularly the increased risk of cardiovascular disease. (2–5) Several large registry-based studies also have demonstrated associations between hypertensive pregnancy disorders (HPDs) and the development of advanced kidney disease, including end-stage renal disease (ESRD).(6–8)

The studies reporting that HPDs are risk factors for ESRD had adequate sample sizes to study ESRD, a rare outcome with an incidence rate of 357 per million in the US population. (9) However, these studies had several important limitations. First, International Classification of Diseases (ICD) codes, rather than a review of the complete medical records using accepted clinical criteria, were used to identify HPDs and relevant co-morbidities. Second, the frequencies of kidney disease and obesity prior to pregnancy, both significant risk factors for preeclampsia and ESRD and therefore potential confounders, could not be determined.(10–12)

We performed a population-based, nested case-control study to determine the magnitude of the association between preeclampsia and ESRD using the complete medical records of cases and controls to identify and confirm preeclampsia, and the US Renal Data System (USRDS) to identify ESRD cases. We also studied how co-morbidities, including decreased kidney function, obesity, hypertension, and diabetes mellitus (DM), prior to pregnancy may be confounding the association between preeclampsia and ESRD.

Methods

Study Setting

We identified a cohort of women who had live or still births during 1976–2010 while residing in Olmsted County, Minnesota, using the unique population-based records-linkage system of the Rochester Epidemiology Project (REP). The REP captures health care information for virtually all individuals who have been residents of Olmsted County from 1966 to the present day.(13–16) All research protocols were approved by the Mayo Clinic and Olmsted Medical Center Institutional Review Boards (numbers 12-001892 and 044-OMC-12, respectively). Informed consent was waived for this study, but only patients who had authorized access to their medical records for research -- approximately 98% of the Olmsted County population -- were considered in this analysis.(15, 16)

ESRD Case Identification and Matched Controls

The definition of ESRD was the need for dialysis (vintage > 3 months) or kidney transplantation. We identified cases from the USRDS, the national data system that has an archive of information about ESRD in the United States going back to 1978. We sent all available patient identifiers for the cohort of women to the USRDS to perform the linkage. The USRDS provided the dates of initiation of dialysis or transplantation, the causes of ESRD, and the co-morbidities that were recorded by the treating physicians at the time of initiation of renal replacement therapy (Center for Medicare & Medicaid Services 2728 forms). Women were excluded if they had ESRD prior to or during any pregnancy.

For each confirmed ESRD case, two women without ESRD (controls) were randomly selected from among all women who had been in contact with a medical care provider of the REP within 3 years of the case's ESRD date. Cases and controls were individually matched for year of birth (± 1 year), age at first pregnancy (± 2 years), and parity (± 1 pregnancy or 4 pregnancies). The 2-to-1 matching was used to increase statistical power.

Data Collection

We reviewed the complete medical records of the cases and controls for each delivery, including prenatal visits and hospital charts. Blood pressure (BP) readings, urine protein measurements, all available laboratory values, patient demographics and co-morbidities were abstracted by 2 reviewers (?.?., ?.?.) and entered into a database. The 2 reviewers had to have 100% agreement in BP and urine protein measurements in 5 charts before data abstraction was allowed to proceed.

Exposure of Interest

The exposure of interest was a preeclamptic pregnancy, including preeclampsia, preeclampsia superimposed on chronic hypertension, and/or eclampsia in any pregnancy. All HPDs, including gestational hypertension, preeclampsia, chronic hypertension, preeclampsia superimposed on chronic hypertension, and eclampsia, were defined by the research team using criteria that are consistent with current clinical practice (Table S1, available as [online supplementary material](#)).⁽¹⁷⁾ An electronic, diagnostic algorithm was developed for the diagnosis of HPD using the data abstracted from medical records. This approach was validated by comparing the diagnoses of HPDs obtained using the algorithm to the gold standard, i.e., diagnoses made by the blinded review of 75 charts (25 with preeclampsia) by 3 maternal-fetal medicine experts (?.?., unpublished preliminary data). The sensitivity for the diagnosis of preeclampsia by algorithm was 100% (95% confidence interval [CI], 83%–100%) and the specificity was 100% (95% CI, 91%–100%).

Briefly, a diagnosis of preeclampsia required new-onset, sustained hypertension (systolic BP > 140 or diastolic BP > 90 mm Hg), and/or the use of an anti-hypertensive medication after 20 weeks' gestation, in combination with new or worsening proteinuria and/or other features indicative of severe disease (elevated liver enzymes, thrombocytopenia, or acute kidney injury). A diagnosis of preeclampsia superimposed on chronic hypertension required worsening of BP after 20 weeks of gestation, or the addition of another anti-hypertensive medication, in addition to the aforementioned criteria for preeclampsia. Finally, a diagnosis of eclampsia required evidence of seizures.

Comorbidities and Risk Factors for Kidney Disease

Obesity was defined as a body mass index (BMI) >30 kg/m² at the first prenatal visit before 20 weeks' gestation in any pregnancy. Diabetes mellitus was defined as having a physician-documented diagnosis of DM, a fasting blood glucose ≥ 126 mg/dl on 2 separate occasions, or positive oral glucose tolerance test results. Gestational DM was not routinely screened for during the majority of the study period, and was not included in the diagnosis of DM. The diagnosis of chronic hypertension unrelated to pregnancy required a physician diagnosis, 2 outpatient systolic BPs >140 mm Hg or diastolic BPs > 90 mm Hg within one year, or the use of an anti-hypertensive medication on two separate outpatient visits. The diagnoses of DM and hypertension were drawn from the USRDS files for those women who had moved out of Olmsted County, MN, after their pregnancies.

Pre-pregnancy serum creatinine (Cr) values and proteinuria values were used to identify pre-existing kidney disease. Serum Cr values from prior to 2006 were standardized via a previously validated equation.⁽¹⁸⁾ We defined pre-existing kidney disease based on either an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m² using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation⁽¹⁹⁾ or by proteinuria. Proteinuria was defined as 1+ proteinuria on dipstick, > 300 mg protein/24 hours, a protein-creatinine ratio > 0.3, or a protein-osmolality ratio > 0.3.⁽²⁰⁾ We considered undetectable to trace protein on dipstick as normal. Abnormal protein values (1+) were only taken from dipsticks without evidence of a urinary tract infection or non-glomerular

hematuria, and 2 abnormal values prior to pregnancy were required to make the diagnosis of pre-existing kidney disease.

Statistical Analysis

Consistent with the matched case-control study design, conditional logistic regression modeling was used to compare characteristics of cases and controls, and to evaluate the association between exposure status (preeclamptic pregnancy) and case-control status. Additional models were fit adjusting independently for the pre-specified confounders of interest, including pre-pregnancy diagnoses of hypertension, DM and obesity (defined as BMI > 30 kg/m² prior to 20 weeks at any first prenatal visit). We also adjusted for characteristics found to be significantly different between cases and controls prior to their first pregnancies (race and education). Each variable had a separate category for missing values. All p-values were two-sided, and p-values less than 0.05 were considered statistically significant. Statistical analyses were performed using the SAS version 9.3 software package (SAS Institute Inc.; Cary, NC).

Results

ESRD Case Identification

We identified 34,581 women with live or stillbirths in 1976–2010 in Olmsted County, MN (Figure 1). After linkage with the USRDS, we identified 48 potential cases, but 5 women were excluded because they had ESRD prior to or during any pregnancy. One additional woman received a kidney transplant after the linkage was performed, and therefore was only found in the REP database. This resulted in a total of 44 confirmed cases. The median time from the last pregnancy to the onset of ESRD was 17.7 (interquartile range [IQR], 10.9–24.2) years, and the median age at diagnosis of ESRD was 45.5 (IQR, 40–53) years.

Patient and Pregnancy Characteristics

The clinical characteristics of the 44 cases and 88 matched controls are listed in Table 1. Age at first birth (either live or still birth) and parity were comparable by design. The majority of pregnancies in both the cases (64%) and controls (80%) were delivered at term (Table S2). Cases were significantly more likely to be non-Caucasian, less educated, obese, and to have DM and hypertension.

Pre-existing Kidney Disease

We identified pre-existing kidney disease in 9 cases and 1 control based on our definitions of reduced eGFR and/or proteinuria (Table 1), but only 5 of these women (50%) had diagnostic codes for kidney disease in the REP database prior to their first pregnancies. Kidney disease was attributed to autosomal dominant polycystic kidney disease (ADPKD; n=4), glomerulonephritis (n=3), and diabetic nephropathy (n=2) in the 9 cases, and autosomal recessive polycystic kidney disease in the 1 control.

A baseline serum Cr value prior to the first pregnancy was available in 20 cases and 32 controls. The median range of serum Cr was 0.65 (IQR, 0.28–0.75) mg/dL in cases and 0.72 (IQR, 0.55–0.75) mg/dl in controls. One case had an eGFR < 60 ml/min/1.73m², and 92% of

cases and controls had an eGFR > 90 ml/min/1.73 m². Baseline urine protein measurements were available in 30 cases and 64 controls. Among the cases, 23 had normal urine dipstick findings, 6 had 1+ protein on urine dipstick, and 2 had 24-hr urine collections with > 1,000 mg protein in 24 hours. Among the controls, 60 had normal urine dipstick findings, 3 had normal protein-osmolality ratios, and 1 had an elevated protein-osmolality ratio.

Hypertensive Pregnancy Disorders

Among the 132 women (44 cases and 88 controls), there were 292 total pregnancies that lasted more than 20 weeks and had sufficient information to evaluate for HPD (Table 2). The median number of measurements from prenatal visits was 11 (IQR, 9–13) for BP and 9 (IQR, 6–11) for urine dipsticks.

Using the diagnostic algorithm for HPDs (Table S1), 18% of the cases and 5% of the controls had at least one preeclamptic pregnancy (Table 2). The frequency of ever having a pregnancy complicated by chronic hypertension was more common in cases (7%) than in controls (0%). The frequency of women with at least one pregnancy affected by gestational hypertension, however, was similar in cases and controls (5% versus 6%). Two cases and 1 control had 2 pregnancies complicated by a HPD. The frequency of women with exclusively normotensive pregnancies was 71% in the cases and 90% in the controls (Table 2).

Preeclamptic Pregnancy

A history of preeclamptic pregnancy occurred more frequently in the cases compared to the controls (unadjusted odds ratio [OR], 4.0; 95% CI, 1.21–13.28; Table 3). The OR remained significant after independent adjustment for race (OR, 4.85; 95% CI, 1.37–17.11), higher education (some college or greater versus high school graduate or less: OR, 5.29; 95% CI, 1.34–20.91), DM (OR, 7.00; 95% CI, 1.45–33.7) or hypertension (OR, 3.68; 95% CI, 1.09–12.47). However, the association was attenuated and no longer statistically significant after adjusting for obesity (OR, 3.25; 95% CI, 0.93–11.37). Similar results were observed when using a broader definition of exposure to include any HPD, including gestational and chronic hypertension (unadjusted OR, 3.34; 95% CI, 1.32–8.47). Table 4 shows the causes of ESRD among women with and without a HPD.

Agreement With Diagnostic Codes

We searched the REP electronic indexes from 1 year prior to the first pregnancy to 1 year after the last pregnancy of all women to identify a set of codes that could be related to a HPD (Table S3). We then searched all 292 pregnancies for any of the aforementioned codes and compared the code-based diagnoses to the algorithm-based diagnoses. The sensitivity of using diagnostic codes for any type of HPD was only 61.5% (95% CI, 40.7%–79.1%), whereas the specificity was 98.1% (95% CI, 95.4%–99.3%). Using codes specifically for preeclampsia, the sensitivity was reduced further to 42.9% (95% CI, 18.8%–70.4%), and the specificity increased to 99.3% (95% CI, 97.2%–99.9%).

Discussion

In the present study, the odds of having ESRD were 4 times greater in women with a history of preeclamptic pregnancy compared to those without, after matching for age and parity. This association remained significant after independent adjustment for race, education, DM, and hypertension prior to a woman's first pregnancy. However, the association was attenuated and no longer significant after adjusting for obesity, suggesting that obesity is a confounder that has not been explored previously. We also found that 20% of women who developed ESRD had laboratory evidence of decreased kidney function prior to their first pregnancies. Although our statistical power was limited, our ability to review the entire medical record allowed us to explore additional confounders that may play a role in the association between preeclampsia and ESRD.

Previous studies investigating the association of HPDs with subsequent ESRD have shown variable magnitudes of risk. In a study involving a population of 570,433 women who gave birth in Norway in 1967–2004, a history of preeclampsia was associated with an almost 5-fold increased risk of ESRD (relative risk, 4.7; 95% CI, 3.6–6.1).⁽⁶⁾ The diagnosis of preeclampsia was determined using ICD codes from the Medical Birth Registry, and women with codes for hypertension, kidney disease, rheumatic disease, or DM before the pregnancy were excluded. Another study from Taiwan that used insurance claims data from 1998–2009 showed a significantly increased risk of ESRD after hypertensive pregnancy (hazard ratio [HR], 12.4; 95% CI, 8.54–18.0).⁽⁷⁾ Women with preeclampsia or eclampsia had a higher risk of ESRD than those with only gestational hypertension. The risk in the Taiwanese women was considerably lower after adjusting for hypertension and DM before the pregnancy (HR, 2.72; 95% CI, 1.76–4.22), demonstrating that pre-pregnancy diseases do confound the association of preeclampsia and ESRD and need to be accounted for when considering any potential causal relationship.

An important limitation of prior studies was that administrative codes were used to diagnose HPDs and co-morbidities. We found that half of the women with laboratory evidence of pre-pregnancy decreased kidney function had no diagnostic codes for kidney disease prior to their pregnancies. This is consistent with a seminal study by Fisher *et al* where investigators performed kidney biopsies for research purposes in 176 women with hypertensive pregnancies within the first week post-partum. Primary kidney disease was present in 20% of biopsies, often unsuspected by providers.⁽²¹⁾ A study by Vikse *et al* found that women with a history of preeclampsia who had low-birth weight infants had an increased risk of having a kidney biopsy later in life. Biopsies in this national cohort revealed a wide variety of renal pathology, from glomerular to tubulointerstitial disease, further emphasizing a possible role of unrecognized kidney disease at the time of preeclamptic pregnancies.⁽²²⁾ The authors raise the point that subclinical kidney disease may be present prior to pregnancy, thereby increasing the risk of preeclampsia, but acknowledged that they did not have access to pre-pregnancy measures of kidney function.

Another limitation of previous studies is that there was no adjustment for obesity at the time of pregnancy, because obesity is often poorly coded in the medical records.⁽¹⁰⁾ Obesity, defined as a BMI >30 kg/m², is associated with a 2- to 3-fold increased risk of preeclampsia

and a 3.5-fold increased risk of ESRD.(12, 23) Therefore, obesity may be a significant confounder between preeclampsia and ESRD, as our data would support. On the other hand, even after adjustment for obesity, the OR was compatible with a more than three-fold increased risk.

The mechanisms that underlie the association between preeclampsia and future ESRD are poorly understood. Preeclampsia is a heterogeneous disorder in which both maternal and placental factors lead to endothelial dysfunction, which manifests in the kidney as glomerular endotheliosis and proteinuria.(24, 25) Given its heterogeneity, it is possible that the relationship between preeclampsia and ESRD is mediated by different mechanisms in different women. First, conditions such as obesity or kidney disease prior to pregnancy may be significant confounders, leading to preeclampsia and ESRD at different times of a woman's life. Second, it is plausible that kidney damage that occurs at the time of preeclamptic pregnancies may have an independent effect on kidney function later in life. There is a growing body of evidence suggesting that podocytopathy, the urinary loss of viable podocytes, may disrupt the glomerular filtration barrier and lead to proteinuria in preeclampsia.(26) Although this injury is thought to be transient,(27) some evidence suggests that moderately increased albuminuria is present for up to 20 years after the hypertensive pregnancy.(28–30) Podocytopathy may be sustained in the post-partum period in some women with preeclampsia, which could reflect ongoing kidney damage or even systemic endothelial dysfunction.(31, 32) Third, women with preeclampsia are at increased risk of hypertension, and may develop hypertension earlier than women with normotensive pregnancies, suggesting that hypertension may be an important mediating factor on the causal pathway from preeclampsia to ESRD.(2, 4, 5, 33–35) Figure 2 shows a schema demonstrating how underlying risk factors may affect the risk of preeclampsia, as well as the future risk of ESRD. It is unknown to what extent preeclampsia increases the risk of ESRD independent of shared risk factors.

This study has several strengths. It is the first study to evaluate the association between preeclampsia and ESRD using extensive review of the entire medical record to confirm the accuracy of clinical information. Our review of the medical records allowed us to accurately identify co-morbidities that may contribute to ESRD, and to identify pre-existing kidney disease in a subset of women. Use of an electronic algorithm prevented bias in the determination of preeclampsia and other HPDs. Lastly, we used the USRDS to identify ESRD cases.

The main limitation of our study is that, although we studied a significant number (n=34,581) of women, the number of cases was small, reflecting the low incidence of advanced kidney disease in general, and in women in particular.(36) We thus had limited power to study the associations of interest. We did not have pre-pregnancy serum Cr or urine protein measurements for all women, limiting our ability to incorporate this data into our models. Lastly, because the population of Olmsted County, Minnesota, is predominantly Caucasian, this might limit generalizability. Of note, there were significantly more non-Caucasian cases than controls; however, adjusting for race did not affect the significance of our results.

Despite these limitations, our study provides strong evidence of a positive association between having a history of preeclampsia and the subsequent development of ESRD in a population-based study in which both exposures and outcomes were confirmed using clinical criteria. The presented results extend our understanding of this association by clearly identifying a subset of preeclamptic women who develop ESRD in the setting of i) kidney disease that predated their pregnancies, which might not have been coded or remained undiagnosed in prior studies, and ii) shared risk factors. However, our study was not adequately powered to assess the role of preeclampsia as an independent risk factor for future ESRD. This study adds to the growing body of evidence that preeclampsia is associated with the future risk of kidney disease, while simultaneously raising questions for future studies that aim to address the potential causal pathways.(6, 7, 29, 30) Preeclampsia may identify women early in life who are at future risk of kidney disease. The optimal follow-up for women with preeclampsia remains unclear; at a minimum, women with preeclampsia should be counseled about the risk of future disease and encouraged to implement lifestyle modifications.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Support: This study was supported by a grant from the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN; the Society for Women's Health Research (Dr Garovic); the National Center for Advancing Translational Science award UL1TR000135); the National Institute on Aging (award P-50 AG44170), the Department of Surgery; and the Mayo Foundation (Drs Miller, Mielke, Rocca, and Garovic). Dr Weissgerber is a Building Interdisciplinary Research Careers in Women's Health (BIRCWH) scholar, supported by BIRCWH K12HD065987. This study used the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health (award R01 AG034676). The data reported here have been supplied by the USRDS. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health or the US government. The funding sources had no role in the study design, collection, analysis, and interpretation of data; writing of the manuscript; or the decision to submit the manuscript for publication.

References

1. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. *Am J Obstet Gynecol.* 2000; 183(1):S1–S22.
2. Garovic VD, Bailey KR, Boerwinkle E, Hunt SC, Weder AB, Curb D, et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. *J Hypertens.* 2010; 28(4):826–833. [PubMed: 20087214]
3. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. *Lancet.* 2001; 357(9273):2002–2006. [PubMed: 11438131]
4. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ.* 2007; 335(7627):974. [PubMed: 17975258]
5. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. *J Am Coll Cardiol.* 2011; 57(12):1404–1423. [PubMed: 21388771]
6. Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. *N Engl J Med.* 2008; 359(8):800–809. [PubMed: 18716297]

7. Wang IK, Muo CH, Chang YC, Liang CC, Chang CT, Lin SY, et al. Association between hypertensive disorders during pregnancy and end-stage renal disease: a population-based study. *Cmaj*. 2013; 185(3):207–213. [PubMed: 23339156]
8. Wu CC, Chen SH, Ho CH, Liang FW, Chu CC, Wang HY, et al. End-stage renal disease after hypertensive disorders in pregnancy. *Am J Obstet Gynecol*. 2014; 210(2):147 e1–147 e8. [PubMed: 24060448]
9. System USRD. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD: 2013. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.
10. Martin BJ, Chen G, Graham M, Quan H. Coding of obesity in administrative hospital discharge abstract data: accuracy and impact for future research studies. *BMC Health Serv Res*. 2014; 14(1): 14–70. [PubMed: 24410755]
11. Saftlas A, Wang W, Risch H, Woolson R, Hsu C, Bracken M. Prepregnancy body mass index and gestational weight gain as risk factors for preeclampsia and transient hypertension. *Ann Epidemiol*. 2000; 10(7):475.
12. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. *Ann Intern Med*. 2006; 144(1):21–28. [PubMed: 16389251]
13. St Sauver JL, Grossardt BR, Yawn BP, Melton LJ 3rd, Pankratz JJ, Brue SM, et al. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. *Int J Epidemiol*. 2012; 41(6):1614–1624. [PubMed: 23159830]
14. St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ 3rd, Rocca WA. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. *Mayo Clin Proc*. 2012; 87(2):151–160. [PubMed: 22305027]
15. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ 3rd. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. *Mayo Clin Proc*. 2012; 87(12):1202–1213. [PubMed: 23199802]
16. St Sauver JL, Grossardt BR, Yawn BP, Melton LJ 3rd, Rocca WA. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. *Am J Epidemiol*. 2011; 173(9):1059–1068. [PubMed: 21430193]
17. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol*. 2013; 122(5):1122–1131. [PubMed: 24150027]
18. Rule AD, Larson TS. Do we need another equation to estimate GFR from serum creatinine in renal allograft recipients? *Nephrol Dial Transplant*. 2008; 23(7):2427–2428. author reply 8. [PubMed: 18400813]
19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009; 150(9):604–612. [PubMed: 19414839]
20. Wilson DM, Anderson RL. Protein-osmolality ratio for the quantitative assessment of proteinuria from a random urinalysis sample. *Am J Clin Pathol*. 1993; 100(4):419–424. [PubMed: 8213637]
21. Fisher KA, Luger A, Spargo BH, Lindheimer MD. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. *Medicine (Baltimore)*. 1981; 60(4):267–276. [PubMed: 7242320]
22. Vikse BE, Irgens LM, Bostad L, Iversen BM. Adverse perinatal outcome and later kidney biopsy in the mother. *J Am Soc Nephrol*. 2006; 17(3):837–845. [PubMed: 16421228]
23. Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. *Am J Obstet Gynecol*. 1997; 177(5):1003–1010. [PubMed: 9396883]
24. Kincaid-Smith P. The renal lesion of preeclampsia revisited. *Am J Kidney Dis*. 1991; 17(2):144–148. [PubMed: 1992654]
25. Suzuki S, Gejyo F, Ogino S, Maruyama Y, Ueno M, Nishi S, et al. Postpartum renal lesions in women with pre-eclampsia. *Nephrol Dial Transplant*. 1997; 12(12):2488–2493. [PubMed: 9430839]

26. Craici IM, Wagner SJ, Weissgerber TL, Grande JP, Garovic VD. Advances in the pathophysiology of pre-eclampsia and related podocyte injury. *Kidney Int.* 2014;275–285. [PubMed: 24573315]
27. Berks D, Steegers EA, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. *Obstet Gynecol.* 2009; 114(6):1307–1314. [PubMed: 19935034]
28. Bar J, Kaplan B, Wittenberg C, Erman A, Boner G, Ben-Rafael Z, et al. Microalbuminuria after pregnancy complicated by pre-eclampsia. *Nephrol Dial Transplant.* 1999; 14(5):1129–1132. [PubMed: 10344350]
29. McDonald SD, Han Z, Walsh MW, Gerstein HC, Devereaux PJ. Kidney disease after preeclampsia: a systematic review and meta-analysis. *Am J Kidney Dis.* 2010; 55(6):1026–1039. [PubMed: 20346562]
30. Kattah AG, Asad R, Scantlebury DC, Bailey KR, Wiste HJ, Hunt SC, et al. Hypertension in pregnancy is a risk factor for microalbuminuria later in life. *J Clin Hypertens (Greenwich).* 2013; 15(9):617–623. [PubMed: 24034653]
31. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. *Diabetologia.* 1989; 32(4):219–226. [PubMed: 2668076]
32. White WM, Garrett AT, Craici IM, Wagner SJ, Fitz-Gibbon PD, Butters KA, et al. Persistent Urinary Podocyte Loss following Preeclampsia May Reflect Subclinical Renal Injury. *PLoS One.* 2014; 9(3):e92693. [PubMed: 24664365]
33. Heida KY, Franx A, van Rijn BB, Eijkemans MJ, Boer JM, Verschuren MW, et al. Earlier Age of Onset of Chronic Hypertension and Type 2 Diabetes Mellitus After a Hypertensive Disorder of Pregnancy or Gestational Diabetes Mellitus. *Hypertension.* 2015:1116–1122.
34. Funai EF, Friedlander Y, Paltiel O, Tiram E, Xue X, Deutsch L, et al. Long-term mortality after preeclampsia. *Epidemiology.* 2005; 16(2):206–215. [PubMed: 15703535]
35. Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. *Hypertension.* 2010; 56(1):166–171. [PubMed: 20516394]
36. Kummer S, von Gersdorff G, Kemper MJ, Oh J. The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease. *Pediatr Nephrol.* 2012; 27(8):1213–1219. [PubMed: 21766172]

Figure 1. Identification of women with end-stage renal disease via linkage

*One case was not identified by USRDS linkage, but was identified by the Rochester Epidemiology Project. This woman received a kidney transplant after the linkage with the USRDS was performed.

Figure 2. Possible explanations for the association between preeclampsia and end-stage renal disease (ESRD)

A. The pathway shown in red depicts the effects of confounding variables. The observed association between preeclampsia and ESRD may be confounded by a common predisposition, shared risk factors, or shared disease processes. B. The pathway shown in blue represents how preeclampsia may contribute to ESRD via metabolic and vascular changes. These changes may lead directly to chronic kidney disease, or via intervening variables, such as hypertension. Both explanations may be true and the association may be partly due to confounding effects and partially causal. The relative contributions of the 2 pathways may vary among women. In either case, recognition of the association has clinical implications.

Table 1

Characteristics in Cases and Controls

Characteristic	Cases (n=44)	Controls (n=88)	p-value *
Age at first live or still birth, y	22 [20–25]	22 [20–26]	0.2
Year of first live or still birth			0.08
1950–1969	7 (16)	11 (13)	
1970–1989	31 (71)	61 (69)	
1990–2010	6 (14)	16 (18)	
Race			0.003
Non-Caucasian	7 (16)	1 (1)	
Caucasian	37 (84)	87 (99)	
Ethnicity			0.2
Not Hispanic	39 (89)	84 (96)	
Hispanic	2 (5)	1 (1)	
Unknown	3 (7)	3 (3)	
Highest Education Level			0.002
<HS graduate	9 (21)	3 (3)	
HS graduate or adult diploma	15 (34)	31 (35)	
Some College	16 (36)	31 (35)	
College graduate	4 (9)	16 (18)	
Unknown	0 (0)	7 (8)	
Gravidity	2.0 [2.0–3.5]	2.5 [2.0–3.0]	0.7
Parity	2.0 [1.0–3.0]	2.0 [2.0–3.0]	0.4
Pre-existing kidney disease [‡]			<0.001
No	24 (55)	77 (88)	
Yes	9 (21)	1 (1)	
Unknown	11 (25)	10 (11)	
Obesity [^] at any first prenatal visit			0.02
No	27 (61)	72 (82)	
Yes	12 (27)	12 (14)	
Unknown	5 (11)	4 (5)	
History of HTN	39 (89)	34 (39)	<0.001 [§]
No	5 (11)	54 (61)	
Before first pregnancy	7 (16)	6 (7)	
Before last pregnancy	2 (5)	1 (1)	
After last pregnancy	30 (68)	27 (31)	
History of Diabetes	21 (48)	10 (11)	<0.001 [§]
No	23 (52)	78 (89)	
Before first pregnancy	7 (16)	0 (0)	
Before last pregnancy	1 (2)	0 (0)	
After last pregnancy	13 (30)	10 (11)	

Note: Values for categorical variables are given as number (percentage); for continuous variables, as median [interquartile range].

HS, high school; HTN, hypertension

* Exact p-value derived from the score statistic from fitting a separate conditional logistic regression model to assess each characteristic.

[†] Defined as an estimated glomerular filtration rate < 60 ml/min/1.73 m² and/or proteinuria prior to first pregnancy.

[§] P-value for the association between case/control status and presence/absence of any history

[^] Obesity defined as body mass index > 30 kg/m².

Table 2

Frequency of Hypertensive Pregnancy Disorders in Cases and Controls

Hypertensive Pregnancy Disorder	Per Woman [*]		Per Pregnancy [†]	
	Cases (n=44)	Controls (n=88)	Cases (n=132)	Controls (n=269)
Normotensive pregnancy	31 (71)	79 (90)	65 (49.2)	201 (74.7)
Gestational HTN	2 (5)	5 (6)	3 (2.3)	6 (2.2)
Chronic HTN	3 (7)	0 (0)	3 (2.3)	0 (0)
Preeclamptic pregnancy	8 (18)	4 (5)	10 (7.6)	4 (1.5)
Probable	2 (5)	3 (3)	3 (2.3)	3 (1.1)
Definite	5 (11)	1 (1)	4 (3.0)	1 (<1)
Superimposed on chronic HTN	1 (2)	0 (0)	3 (2.3)	0 (0)
Probable/Definite eclampsia	0 (0)	0 (0)	0 (0)	0 (0)
Pregnancies with unknown exposure [‡]				
Insufficient pregnancy data	0 (0)	0 (0)	29 (22.0) [§]	16 (6.0)
Pregnancy <20 wk	0 (0)	0 (0)	22 (16.7)	42 (15.6)

Note: Values are given as number (percentage).

HTN, hypertension

^{*} All women classified according to most severely affected pregnancy or as normotensive if no pregnancy was complicated by a hypertensive pregnancy disorder.

[†] There were a total of 401 pregnancies in the 44 cases (n=132) and 88 controls (n=269), but only 292 with sufficient information to evaluate for HPD.

[‡] Pregnancies with unknown exposure included pregnancies with insufficient data (occurred outside of Olmsted County, MN) and pregnancies less than 20 weeks, including spontaneous and therapeutic abortions. All women had to have at least one pregnancy lasting > 20 weeks in Olmsted County, MN to be included in the cohort.

[§] Includes eleven pregnancies from 2 different cases that occurred outside of Olmsted County, MN.

Table 3

Case-Control Analyses for history of pre-eclamptic pregnancy

	OR (95% CI)	p-value [†]
Unadjusted	4.00 (1.21–13.28)	0.02
Adjusted for		
Race	4.85 (1.37–17.11)	0.01
Higher education [‡]	5.29 (1.34–20.91)	0.02
HTN	3.68 (1.09–12.47)	0.04
Diabetes	7.00 (1.45–33.70)	0.02
Obesity [§]	3.25 (0.93–11.37)	0.07

Note: Analyses of 44 cases (8 [18%] affected) and 88 controls (4 [5%] affected).

CI, confidence interval; HTN, hypertension; OR, odds ratio

* Includes preeclampsia (definite or probable), preeclampsia superimposed on chronic HTN, and eclampsia

[†] p-values were derived using conditional logistic regression modeling

[‡] Includes some college, college graduate or more as compared to less than high school, high school graduate or adult diploma. Missing values were coded as 'missing' and included in model.

[§] Missing values were coded as 'missing' for obesity status and included in model.

Table 4

Primary Cause of ESRD by Most Severe Hypertensive Pregnancy Disorder

Primary cause	All normotensive (n=31)	Preeclampsia [†] (n=8)	Chronic or Gestational HTN (n=5)
Diabetes Mellitus	11 (36)	3 (38)	2 (40)
Polycystic Kidney Disease	2 (7)	3 (38)	1 (20)
HTN	0 (0)	0 (0)	1 (20)
Acute Tubular Necrosis	2 (7)	0 (0)	0 (0)
Glomerulonephritis	8 (26)	1 (13)	0 (0)
Chronic Obstruction	1 (3)	0 (0)	1 (20)
Unknown Etiology	4 (13)	1 (13)	0 (0)
Other	3 (10)	0 (0)	0 (0)

Note: Values are given as number (percentage). For women who had more than one hypertensive pregnancy disorder, only the most severe was considered in this analysis. Chronic and gestational HTN were combined into one category.

ESRD, end-stage renal disease; HTN, hypertension

[†]Includes preeclampsia (definite or probable), preeclampsia superimposed on chronic HTN, and eclampsia